These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34350076)

  • 1. Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves.
    Akram A
    Cureus; 2021 Jul; 13(7):e16112. PubMed ID: 34350076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
    Timmins P; Donahue S; Meeker J; Marathe P
    Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs.
    Al-Abri SA; Hayashi S; Thoren KL; Olson KR
    Clin Toxicol (Phila); 2013 Jun; 51(5):444-7. PubMed ID: 23544622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
    Buse JB; DeFronzo RA; Rosenstock J; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetes Care; 2016 Feb; 39(2):198-205. PubMed ID: 26285584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis.
    Tarry-Adkins JL; Grant ID; Ozanne SE; Reynolds RM; Aiken CE
    Diabetes Ther; 2021 Jul; 12(7):1901-1914. PubMed ID: 34075573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy.
    Chacra AR
    Am J Ther; 2014; 21(3):198-210. PubMed ID: 22314210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
    Sobieraj DM; Freyer CW
    Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life-threatening metabolic coma caused by levofloxacin.
    Bansal N; Manocha D; Madhira B
    Am J Ther; 2015; 22(2):e48-51. PubMed ID: 23896743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypoglycemia in an elderly patient treated with metformin.
    Zitzmann S; Reimann IR; Schmechel H
    Int J Clin Pharmacol Ther; 2002 Mar; 40(3):108-10. PubMed ID: 11911598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
    Bhansali A; Masoodi SR
    J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review.
    Tan J; Wang Y; Liu S; Shi Q; Zhou X; Zhou Y; Yang X; Chen P; Li S
    Front Pharmacol; 2021; 12():669814. PubMed ID: 34079464
    [No Abstract]   [Full Text] [Related]  

  • 15. Metformin extended release: metformin gastric retention, metformin GR, metformin XR.
    Drugs R D; 2005; 6(5):316-9. PubMed ID: 16128603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release.
    Hameed M; Khan K; Salman S; Mehmood N
    J Ayub Med Coll Abbottabad; 2017; 29(2):225-229. PubMed ID: 28718236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypoglycemia due to antibodies to exogenous insulin in a patient with type 2 diabetes – a case report of treatment with new generation oral hypoglycemic agents].
    Ucieklak D; Zięba-Parkitny J; Kozek E; Skupień J; Sztefko K; Małecki MT
    Przegl Lek; 2017; 74(1):41-3. PubMed ID: 29694001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe lactic acidosis and hypoglycemia due to acute metformin intoxication in a dog.
    Ueda Y; Wong C; Borchers A
    J Vet Emerg Crit Care (San Antonio); 2018 May; 28(3):274-278. PubMed ID: 29687945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of extended-release metformin in patients with type 2 diabetes mellitus.
    Jabbour S; Ziring B
    Postgrad Med; 2011 Jan; 123(1):15-23. PubMed ID: 21293080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus.
    Levy J; Cobas RA; Gomes MB
    Diabetol Metab Syndr; 2010 Mar; 2():16. PubMed ID: 20298568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.